Lonza Group AG / Key word(s): Personnel
Changes to the Composition of the Lonza Board
13.02.2026 / 09:00 CET/CEST
- Sami Atiya is nominated to the Lonza Board for his deep experience in healthcare, robotics, automation and AI acquired from senior roles at ABB, Siemens and other leading companies.
- Subject to election at the AGM, Sami will also be appointed a member of the Lonza Board Strategy and Innovation Committee.
- Recently nominated as an Independent Member of the Board, and also subject to election at the AGM, Claudia Süssmuth-Dyckerhoff will be appointed Vice-Chair of the Board and a member of the Remuneration Committee and the Strategy and Innovation Committee.
- At the 2026 AGM, Jürgen Steinemann, Barbara Richmond will not stand for re-election, as they reach their maximum Lonza Board tenures. Roger Nitsch has also decided not to stand for re-election, in order to focus on his entrepreneurial activities.
Basel, Switzerland, 13 February 2026 – Today, the Lonza Board of Directors announced the nomination of Sami Atiya as an Independent Member of the Board. The Board will propose Sami’s election to shareholders at the Lonza Group Annual General Meeting (AGM) in May 2026. Subject to his election at the AGM, Sami will also be appointed a member of the Strategy and Innovation Committee.
Sami brings extensive leadership experience in healthcare, robotics, automation and AI, all of which are highly relevant to Lonza’s core business. Most recently, Sami spent ten years on the Group Executive Committee of ABB Ltd, with responsibilities across robotics, motion and discrete automation. Prior to this, Sami spent more than 15 years in leadership at Siemens, including responsibility for the Siemens Computer Tomography and Radiation Oncology business. Sami is on the Board of Directors of SGS and the AI Council of the Port Authority of Singapore. Sami holds an MBA from the Massachusetts Institute of Technology (USA), as well as a PhD in Engineering and an MSc in Electrical Engineering from the University of Wuppertal and Karlsruhe (DE).
As previously announced, the Board’s long-term succession planning is further supported by the nomination of Claudia Süssmuth-Dyckerhoff as Vice-Chair of the Lonza Board, bringing a decade of Board experience at companies including Roche. Marion Helmes will transition to Chair of the Audit and Compliance Committee. All nominations demonstrate a structured approach to leadership team succession planning and continuity, in line with the commitment to ensuring robust governance.
As previously announced, Jürgen Steinemann and Barbara Richmond will not stand for re-election at the 2026 AGM following their twelve-year tenures with Lonza. Roger Nitsch, who joined the Lonza Board in 2022, has also decided not to stand for re-election, in order to focus on his other entrepreneurial activities.
Jean-Marc Huët, Chairman of the Board, Lonza, commented: “I am delighted to congratulate Sami on his nomination. With extensive experience in new technologies, such as robotics and automation, Sami’s skillset is highly relevant to our company and business. Together with Claudia Süssmuth-Dyckerhoff, Sami will be an invaluable addition to the Board. I am also very thankful to Barbara, Jürgen and Roger for their continued service, collaboration and contribution to Lonza’s success, and I take this chance to wish them every happiness after they leave the Lonza Board.” Notes to Editors: The follow materials are available for download: About Lonza Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Find out more at www.lonza.com Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes. Privacy Policy link To immediately delete all the data
End of Media Release
View original content: EQS News
|
